A newly published study has shed light on how sotagliflozin, a medicine used to treat certain patients with diabetes and heart-related conditions, may help lower the risk of heart attacks and strokes. Researchers found that the drug may offer benefits beyond controlling blood sugar by reducing the activity of platelets, blood components involved in clot formation.
How the Medicine May Reduce Blood Clot Formation
Researchers examined how sotagliflozin affects platelets, which can stick together and form clots that block blood flow to vital organs. Excessive clotting can contribute to serious cardiovascular events, including heart attacks and certain types of strokes.
In laboratory experiments, sotagliflozin reduced platelet activation in blood samples from healthy volunteers and people with type 2 diabetes. The researchers also observed that the medicine made platelets less likely to clump together.
Comparison With Another Diabetes Drug
The study compared sotagliflozin with empagliflozin, another medicine used to manage type 2 diabetes. While sotagliflozin limited platelet activation, empagliflozin showed little to no effect in the same laboratory tests.
Experiments involving mice with injured blood vessels also found a difference in clot formation. The reduction was approximately 60% in mice treated with sotagliflozin, compared with around 5–10% in those given empagliflozin.
These findings help explain why the two medicines may have different effects on blood clotting. However, results from laboratory and animal experiments do not automatically establish the same effects in every patient.
What the Findings Mean for Patients
Sotagliflozin works by targeting two types of sodium-glucose cotransporter proteins involved in glucose absorption. Researchers believe its effects on platelets may help explain some of its cardiovascular benefits.
The team says further research is needed to understand the precise mechanisms involved and explore the medicine’s potential in other conditions.
The findings offer a new direction for cardiovascular research, particularly for people living with diabetes who also face an increased risk of heart disease. Patients should continue taking prescribed medicines as directed and should not change their treatment based on early research findings.
